Press release
Chronic Hepatitis B (CHB) Market Set to Witness Significant Growth by 2025-2034
Chronic Hepatitis B (CHB) Market
Chronic Hepatitis B (CHB) is a serious viral infection of the liver caused by the hepatitis B virus (HBV). It remains a major global public health challenge, affecting nearly 300 million people worldwide. CHB can lead to cirrhosis, liver failure, and hepatocellular carcinoma (HCC), making it one of the leading causes of liver-related morbidity and mortality.
While effective vaccines exist for prevention, there is no universal cure for chronic infection. Current therapies - primarily nucleos(t)ide analogs (NAs) and interferons - focus on viral suppression rather than eradication. However, with new drug classes, immune modulators, and gene-editing technologies under development, the CHB market is on the brink of transformation.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71722
Market Overview
The global Chronic Hepatitis B (CHB) market was valued at USD 5.4 billion in 2024 and is projected to reach USD 9.8 billion by 2034, growing at a CAGR of 6.2% during the forecast period.
Key Highlights
• Market Size 2024: Estimated at USD 5.4 billion
• Forecast 2034: Expected to reach USD 9.8 billion
• CAGR (2025-2034): 6.2%
Market Drivers
• Rising prevalence of chronic HBV infection, particularly in Asia-Pacific and Africa.
• Growing adoption of antiviral therapies to prevent progression to cirrhosis and liver cancer.
• Expansion of global vaccination and screening programs.
• Strong pipeline of immune modulators, siRNA drugs, and therapeutic vaccines.
Market Challenges
• Lack of curative therapies; current treatments are lifelong.
• High disease burden in regions with limited healthcare access.
• Stigma associated with hepatitis B reduces patient diagnosis and treatment rates.
Leading Players
Key companies active in the CHB market include Gilead Sciences, Johnson & Johnson (Janssen), Bristol Myers Squibb, GlaxoSmithKline, Arrowhead Pharmaceuticals, Alnylam Pharmaceuticals, Vir Biotechnology, Arbutus Biopharma, Roche, and Novartis AG.
Segmentation Analysis
By Product
• Nucleos(t)ide Analogs (Tenofovir, Entecavir, Others)
• Interferon Therapy
• siRNA-Based Therapies
• Immune Modulators
• Therapeutic Vaccines
• Gene Editing/Gene Silencing Candidates
By Technology
• Oral Therapy
• Injectable Therapy
• Gene Editing & RNAi Platforms
By End Use
• Hospitals
• Specialty Clinics
• Research Institutes
• Homecare Settings
By Application
• Viral Suppression
• Liver Disease Management (Cirrhosis, HCC Prevention)
• Curative Therapies (Pipeline Candidates)
Summary:
The market is currently dominated by oral nucleos(t)ide analogs, but future growth will be fueled by siRNA-based therapies, therapeutic vaccines, and immune modulators. The shift from viral suppression to curative intent is expected to redefine long-term market dynamics.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/71722/chronic-hepatitis-b-market
Regional Analysis
• North America
Holds a major share, driven by robust healthcare infrastructure, high diagnosis rates, and adoption of advanced antivirals. The U.S. leads with active clinical trials in RNAi and immune-modulating drugs.
• Europe
Second-largest market, supported by strong healthcare systems and reimbursement policies. Countries like Germany, the UK, and France lead in access to advanced therapies.
• Asia-Pacific
Accounts for the highest patient population, with China and India bearing the largest HBV burden. Government programs for vaccination and screening, along with growing R&D, position the region as the fastest-growing market.
• Middle East & Africa
High prevalence rates, particularly in sub-Saharan Africa. Limited infrastructure and affordability issues restrict advanced therapy adoption, though international health partnerships are expanding access.
• Latin America
Emerging opportunities in Brazil and Mexico, supported by government vaccination programs and international collaborations.
Regional Summary:
While North America and Europe dominate current revenues, Asia-Pacific represents the largest patient base and fastest-growing region, offering significant opportunities for companies investing in accessible and innovative therapies.
Market Dynamics
Key Growth Drivers
• Expanding global vaccination and screening initiatives.
• Rapid development of siRNA and immune-modulating therapies.
• Rising investment in curative HBV research.
• Increasing awareness through global health organizations and patient advocacy.
Key Challenges
• Current therapies are non-curative and require lifelong adherence.
• High unmet needs in low-resource settings.
• Stigma and lack of awareness continue to delay treatment initiation.
Latest Market Trends
• Clinical trials for therapeutic vaccines and siRNA-based drugs showing strong efficacy.
• Growing focus on combination therapies to achieve functional cure.
• Expansion of AI-driven drug discovery in HBV treatment pipelines.
• Partnerships between pharma companies and NGOs to broaden treatment access.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71722
Competitor Analysis
Major Players
• Gilead Sciences - Market leader with tenofovir-based antivirals.
• Johnson & Johnson (Janssen) - Strong portfolio in immune modulators.
• Bristol Myers Squibb - Developer of entecavir and other antivirals.
• GlaxoSmithKline - Active in therapeutic vaccine development.
• Arrowhead Pharmaceuticals - Advancing RNAi-based HBV therapies.
• Alnylam Pharmaceuticals - Focused on RNA interference platforms.
• Vir Biotechnology - Collaborating on HBV immune-modulating treatments.
• Arbutus Biopharma - Early-stage research in siRNA therapies.
• Roche - Expanding presence in liver disease biologics.
• Novartis AG - Diversifying rare disease and viral infection portfolio.
Competitive Landscape Summary:
The CHB market is undergoing a paradigm shift. While established players like Gilead and BMS dominate antivirals, biotech innovators such as Arrowhead, Alnylam, and Vir Biotechnology are pushing toward curative approaches. Strategic collaborations, licensing deals, and clinical trial accelerations are shaping the future competitive environment.
Conclusion
The Chronic Hepatitis B (CHB) market is projected to grow from USD 5.4 billion in 2024 to USD 9.8 billion by 2034, at a CAGR of 6.2%. The next decade will see a transition from lifelong viral suppression therapies to curative and immune-modulating solutions.
While challenges such as affordability, stigma, and infrastructure gaps persist, global initiatives and pharmaceutical innovation are expected to bridge these barriers.
Outlook:
North America and Europe remain key revenue drivers, but Asia-Pacific represents the largest and fastest-growing opportunity, given its high disease burden. Companies that successfully deliver curative, affordable, and patient-friendly therapies will lead the market through 2034 and beyond.
This report is also available in the following languages : Japanese (慢性B型肝炎市場), Korean (만성 B형 간염 시장), Chinese (慢性乙型肝炎市场), French (Marché de l'hépatite B chronique), German (Markt für chronische Hepatitis B), and Italian (Mercato dell'epatite B cronica), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71722
Our More Reports:
Asia-Pacific Hernia Repair Devices Market
https://exactitudeconsultancy.com/reports/72330/asia-pacific-hernia-repair-devices-market
North America Hernia Repair Devices Market
https://exactitudeconsultancy.com/reports/72331/north-america-hernia-repair-devices-market
EU5 Gastric Bands and Balloons Market
https://exactitudeconsultancy.com/reports/72332/eu5-gastric-bands-and-balloons-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Hepatitis B (CHB) Market Set to Witness Significant Growth by 2025-2034 here
News-ID: 4177647 • Views: …
More Releases from Exactitude Consultancy
Triple X Syndrome Market to Reach USD 400 Million by 2034
Triple X syndrome, also known as 47,000 or Trisomy X, is a rare chromosomal disorder in females caused by the presence of an extra X chromosome. Most affected individuals may not show significant physical abnormalities but can present with developmental delays, learning disabilities, language difficulties, and sometimes tall stature or motor coordination issues. In some cases, fertility and normal lifespan are preserved, but psychosocial support and early interventions are crucial…
Tay-Sachs disease market is expected to reach USD 710 million by 2034
Tay-Sachs disease is a rare, inherited lysosomal storage disorder caused by mutations in the HEXA gene, leading to deficiency of the enzyme beta-hexosaminidase A. This results in the accumulation of GM2 ganglioside in nerve cells, progressively damaging the central nervous system. Tay-Sachs is most common in infants, but juvenile and adult-onset forms also exist.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71703
The condition is devastating, with no current cure,…
Von Willebrand Disease (VWD) Market 2025-2034 Business Outlook, Critical Insight …
Introduction
Von Willebrand Disease (VWD) is the most common inherited bleeding disorder, caused by deficiencies or dysfunction in the von Willebrand factor (VWF), a protein essential for blood clotting. It affects both men and women, with symptoms ranging from frequent nosebleeds and easy bruising to severe hemorrhages during surgery or childbirth. Although often underdiagnosed, VWD poses a significant global healthcare challenge.
The therapeutic landscape has expanded with the development of replacement therapies,…
Recessive Dystrophic Epidermolysis Bullosa (RDEB) market is expected to reach US …
Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a rare, inherited connective tissue disorder caused by mutations in the COL7A1 gene, which impairs the production of type VII collagen. This results in fragile skin prone to blistering and chronic wounds even from minor friction or trauma. RDEB is one of the most severe forms of epidermolysis bullosa (EB), often leading to severe pain, recurrent infections, scarring, and increased risk of squamous cell…
More Releases for CHB
Chronic Hepatitis B (CHB) Market Set for Rapid Growth
Chronic hepatitis B is a serious viral infection that leads to liver inflammation and can result in severe liver damage. The hepatitis B virus (HBV) primarily spreads through contaminated blood. Diagnosis involves several tests, including antibody tests, genotype tests, and viral load tests. Treatment options include antiviral drugs and immune modulators.
𝐆𝐞𝐭 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.alliedmarketresearch.com/request-sample/A31523
Key Market Drivers
• Increased Blood Transfusion Rates: The rise in blood transfusions necessitates…
Canned Fruits Market Is Booming Worldwide | Kronos, Acroyali, CHB Group
The "Canned Fruits Market" intelligence report, just published by USD Analytics Market, covers a micro-level study of important market niches, product offers, and sales channels. to determine market size, potential, growth trends, and competitive environment, the Canned Fruits Market provides dynamic views. Both primary and secondary sources of data were used to generate the research, which has both qualitative and quantitative depth. Several of the major figures the study featured…
Chronic Hepatitis B (CHB) Market Opportunities, Share, & Analysis by 2031
Hepatitis B is a viral infection that causes liver inflammation and damage. Inflammation is swelling that occurs when tissues of the body become injured or infected. Inflammation can damage organs. Chronic hepatitis B is a long-lasting infection. According to National Institutes of Health (NIH), about 90% of infants infected with hepatitis B develop a chronic infection. About 25 to 50% of children infected between the ages of 1 and 5…
Fruit Segments Market In-depth Analysis| 2028 Eminent Players - Del Monte, Dole, …
Global Fruit Segments Market Size was estimated at USD 10030 million in 2021 and is projected to reach USD 12670 million by 2028, exhibiting a CAGR of 3.4% during the forecast period.
Report Overview:
Global Fruit Segments Market Report 2022 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through…
Emergency Food Market to Develop New Growth by Top Vendors PepsiCo, The Coca-Col …
The key players profiled in this report include the key companies profiled in the report include Nestle S.A., Kraft Foods Group Inc., General Mills Inc., Kellogs, Conagra Brands Inc., PepsiCo, The Coca-Cola Company, Del Monte Foods Inc., CHB, and Princes Limited.
Request Sample Report: https://www.alliedmarketresearch.com/request-sample/5235
The global emergency food market size was valued at $5,169 million in 2017, and is projected to reach $6,142 million by 2025, growing at a CAGR of…
Canned Food Market Trends by Leading Key Players Kraft Heinz, Nestl, JBS, CHB G …
Key findings of the Study:
The canned food market was valued at $ 91.4 billion in 2018 and is estimated to reach $124.8 billion by 2026, growing at a CAGR of 3.9% during the forecast period.
By type, the organic segment is estimated to witness the fastest growth, registering a CAGR of 6.4% during the forecast period.
In 2018, by distribution channel, the supermarket/hypermarket segment held the highest share, accounting for one third…
